Glaxo gets priority review for lung cancer drug
GlaxoSmithKline said on Tuesday that U.S. health regulators granted a priority review to a capsule form of its drug Hycamtin for the treatment of relapsed small cell lung cancer.
This entry was posted on Tuesday, June 12th, 2007 at 5:34 pm and is filed under Research, Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.